Polymer Laboratories, Varian, Inc. - - BioPharm International

ADVERTISEMENT

Polymer Laboratories, Varian, Inc.

BioPharm International
Volume 19, Issue 12

Company Description



Polymer Laboratories (PL), now a part of Varian, Inc., specializes in the development and manufacture of high grade polymeric particles for HPLC columns, nano through process, solid and solution phase synthesis supports for high throughput organic synthesis and peptide synthesis, and polymers for clinical diagnostics, including paramagnetic particles for bioseparations.

PL's media and resins are manufactured under the ISO 9001:2000 Quality Management System. The company has a 30 years experience in polymers and polymer particles for high-technology applications.

Polymer Laboratories became part of Varian, Inc. in November 2005.



Biopharmaceutical Techniques Supported
  • Synthesis
  • Analysis
  • Purification

Markets Served

  • Biotherapeutic synthesis and purification
  • Biomolecule synthesis and purification
  • Diagnostics



Products and Services
  • HPLC columns and media
  • Synthesis supports
  • Paramagnetic particles

Facilities

State-of-the-art manufacturing facilities opened in 2001, with a capacity greater than 4 M tonnes of high-performance particles, establishing PL as one of the world's largest chromatographic and solid phase synthesis particle manufacturers, which is ISO 9001:2000 accredited.











Stringently controlled specialist production of particles for biological application.

















POLYMER LABORATORIES
Now a Part of Varian, Inc.
Amherst Fields Research Park, 160 Old Farm Road, Amherst, MA 01002

TELEPHONE
413 253 9554
413 253 2476

EMAIL

WEB ADDRESS
http://www.polymerlabs.com/
http://www.varianinc.com/

EMPLOYEES
PL: 160
Varian: 3,700

FOUNDED
PL: 1976
Varian Associates: 1948
Varian Inc.: 1999

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here